The Effect of Conduction Exercise and Self-Acupressure in Treatment of Parkinson’s Disease: A Pilot Study
Table 1
Baseline demographics.
CE and SA group (N = 22)
Control group (N = 14)
value
Age (years)
63.77 ± 1.41
64.64 ± 2.57
0.75
Gender (M/F)†
9/13
4/10
0.45
Disease duration (years)
8.41 ± 1.27
8.64 ± 1.44
0.91
Duration of levodopa treatment (years)
5.47 ± 1.35
6.36 ± 1.47
0.67
Daily levodopa equivalent dose (mg)
491.77 ± 65.36
541.86 ± 86.31
0.64
Other antiparkinsonian drugs†
Dopamine agonist, n (%)
12 (54.5)
7 (50.0)
0.79
Muscarinic antagonist, n (%)
7 (0.32)
3 (21.4)
0.71
COMT inhibitor, n (%)
1 (4.5)
1 (7.1)
1.00
MAO-B inhibitor, n (%)
9 (40.9)
5 (35.7)
0.76
Clonazepam, n (%)
3 (13.6)
1 (7.1)
1.00
Amantadine, n (%)
0 (0)
3 (21.4)
0.051
Data are expressed in the format of mean ± SEM; value was used to indicate the difference between the two groups in baseline, calculated with independent t-test; †the value was calculated using chi-square test or Fisher’s exact test.
